| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2015-06-03 | Apogenix (Germany) | nomination |
Cancer - Oncology | Nomination | ||
| 2015-06-02 | Oncodesign (France) UCB (Belgium) | selective inhibitors of a kinase target selected by UCB | R&D |
Neurodegenerative diseases - Neurological diseases | Exercise of an option agreement | |
| 2015-06-02 | Genmab (Denmark) BMS (USA - NY) | human antibodies against CD19 | hematologic cancers | licensing |
Cancer - Oncology | Licensing agreement |
| 2015-06-02 | Aduro Biotech (USA - CA) | nomination |
Nomination | |||
| 2015-06-02 | Anergis (Switzerland) | nomination |
Allergic diseases | Nomination | ||
| 2015-06-02 | Amag Pharmaceuticals (USA - MA) | nomination |
Nomination | |||
| 2015-06-02 | Cellectis (France) Weill Cornell Medical College (USA - NY) | UCART123 | acute myelogenous leukemia (AML) | R&D | Cancer - Oncology | R&D agreement |
| 2015-06-02 | Nektar Therapeutics (USA - CA) The University of Texas MD Anderson Cancer Center (USA - TX) | NKTR-214 | clinical research |
Clinical research agreement | ||
| 2015-06-02 | Anergis (Switzerland) | chief development officer | nomination | Allergic diseases - Inflammatory diseases - Respiratory diseases | Nomination | |
| 2015-06-01 | BioInvent (Sweden) University of Southampton (UK) | antibodies targeting human T regs | R&D |
Cancer - Oncology | R&D agreement | |
| 2015-06-01 | Active Biotech (Sweden) | restructuring |
Cancer - Oncology | Restructuring | ||
| 2015-05-30 | Poietis (France) | director of product development, chief technology officer | nomination | Technology - Services | Nomination | |
| 2015-05-29 | Neostem (USA - NY) now Caladrius Biosciences (USA - NY) | restructuring | Technology - Services - Cancer - Oncology - Cardiovascular diseases - Metabolic diseases | Restructuring | ||
| 2015-05-28 | Juno Therapeutics (USA - WA) | nomination |
Cancer - Oncology - Rare diseases | Nomination | ||
| 2015-05-27 | Biocartis (Belgium) Fast-track diagnostics (Luxembourg) | multiplex infectious disease tests to run on the Biocartis Idylla™ system | upper respiratory tract infections | development collaboration |
Infectious diseases - Diagnostic | Development agreement |
| 2015-05-27 | Halozyme Therapeutics (USA - CA) Ventana Medical Systems,(USA), a member of the Roche Group (Switzerland) | companion diagnostic assay for use with PEGPH20 | collaboration |
Cancer - Oncology | Collaboration agreement | |
| 2015-05-27 | Zafgen (USA - MA) | nomination |
Rare diseases - Genetic diseases - Metabolic diseases | Nomination | ||
| 2015-05-27 | RegenXBio (USA - MD) | nomination |
Rare diseases - Genetic diseases | Nomination | ||
| 2015-05-27 | Poxel (France) | nomination |
Metabolic diseases | Nomination | ||
| 2015-05-26 | Bluebird bio (USA - MA) Five Prime Therapeutics (USA - CA) | chimeric antigen receptor (CAR) T cell therapies | hematologic malignancies, solid tumors | development commercialisation |
Cancer - Oncology | Development agreement |
